SLI 381

Drug Profile

SLI 381

Alternative Names: Adderall XR; Amfetamine salts (mixed, extended release) - Shire; Amphetamine salts (mixed, extended release) - Shire; d,l-Amphetamine and d-amphetamine salts (extended release) - Shire; d,l-Amphetamine and dextroamphetamine salts (extended release) - Shire; d-Amphetamine and d,l-amphetamine salts (extended release) - Shire; Dexamfetamine and d,l-amfetamine salts (extended release) - Shire; Dextroamphetamine and d,l-amphetamine salts (extended release) - Shire

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 23 Mar 2018 US District Court of Massachusetts issues a ruling against Abhai's marketing of a generic version of Shire's SLI 381
  • 20 Feb 2018 Shire has patent protection for SLI 381 in USA
  • 25 Feb 2011 Shire receives Paragraph IV Notice Letter from Watson Laboratories advising of the filing of an Abbreviated NDA for a generic version of all approved strengths of SLI 381
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top